• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D filed by Singular Genomics Systems Inc.

    11/5/24 7:29:21 PM ET
    $OMIC
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $OMIC alert in real time by email
    SC 13D 1 sc13d.htm SC 13D

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13D
    Under the Securities Exchange Act of 1934
    (Amendment No. ________)*
     
     
    Singular Genomics Systems, Inc.
    (Name of Issuer)
     
     Common Stock, par value $0.0001 per share
    (Title of Class of Securities)
     
     82933R308
    (CUSIP Number)
     
     Chun R. Ding
    c/o CRCM LP
    475 Sansome Street, Suite 730
    San Francisco, CA 94111
    (415) 578-5700
    (Name, Address and Telephone Number of Person
    Authorized to Receive Notices and Communications)
     
     October 30, 2024
    (Date of Event which Requires Filing of this Statement)

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box ☐.

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
     

     

     
    1
    NAMES OF REPORTING PERSONS
     
     
    CRCM Institutional Master Fund (BVI), Ltd.
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐
     
    (b)
    ☐
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    WC
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐
     
     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    British Virgin Islands
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    140,974
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    140,974
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    140,974
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐
     
     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    5.6%
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    CO
     
     
     
     
     

    2



    1
    NAMES OF REPORTING PERSONS
     
     
    CRCM LP
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐
     
    (b)
    ☐
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐
     
     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    140,974
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    140,974
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    140,974
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐
     
     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    5.6%
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    PN
     
     
     
     



    3



    1
    NAMES OF REPORTING PERSONS
     
     
    CRCM LLC
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐
     
    (b)
    ☐
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐
     
     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    140,974
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    140,974
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    140,974
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐
     
     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    5.6%
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     



    4



    1
    NAMES OF REPORTING PERSONS
     
     
    Chun R. Ding
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐
     
    (b)
    ☐
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐
     
     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    St. Kitts & Nevis
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    140,974
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    140,974
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    140,974
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐
     
     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    5.6%
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    IN
     
     
     
     



    5


    Item 1.  Security and Issuer.

    This Statement on Schedule 13D (this “Statement”) relates to shares of Common Stock, par value $0.0001 per share (the “Common Stock” or “Shares”) of Singular Genomics Systems, Inc., a Delaware corporation (the “Issuer”). The address of the principal executive offices of the Issuer is 3010 Science Park Road, San Diego, CA 92121.

    Item 2.  Identity and Background.

    a. Name

    This Statement is being filed by: (i)  CRCM Institutional Master Fund (BVI), Ltd., a British Virgin Islands limited company (the “Fund”); (ii) CRCM LP, a Delaware limited partnership (the “Investment Manager”); (iii) CRCM LLC, a Delaware limited liability company (the “General Partner”); and (iv) Chun R. Ding, a citizen of St. Kitts & Nevis (collectively, the “Reporting Persons”).
    b. Residence or Business Address

    The business address of (i) the Fund is c/o Intertrust (BVI) Limited, Luna Tower Waterfront Drive, Road Town, Tortola, British Virgin Islands VG1110; and (ii) the Investment Manager, the General Partner and Chun R. Ding is 475 Sansome Street, Suite 730, San Francisco, CA 94111.

    c. Occupation

    The principal business of the Fund is that of a private investment fund engaging in the purchase and sale of investments for its own account.  The principal business of the Investment Manager is to act as the investment manager to the Fund and other clients.  The principal business of the General Partner is to act as the general partner of the Investment Manager.  The principal occupation of Chun R. Ding is to serve as the managing member of the General Partner, the principal of the Investment Manager and a director of the Fund.

    d. Convictions

    None of the Reporting Persons has, during the last five years, been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).

    e. Civil Judgments

    None of the Reporting Persons has, during the last five years, been party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

    f. Citizenship

    See item 6 on the cover pages.

    Item 3.  Source or Amount of Funds or Other Consideration.

    The Fund acquired the beneficial ownership in the Shares reported in this Statement for a total consideration of $2,314,284.65 (excluding brokerage commissions).  The source of funds for such transactions was derived from the capital of the Fund.

    Item 4.  Purpose of Transaction.


    The purpose of the acquisitions of the Shares was and is for investment, and acquisitions of the beneficial ownership in the Shares were made in the ordinary course of business, and the Reporting Persons did not acquire the Shares with any purpose, or with the effect, of changing or influencing the control of the Issuer.

    6


    Although no Reporting Person has any specific plan or proposal to acquire or dispose of the Shares, consistent with its investment purpose, each Reporting Person at any time and from time to time may acquire additional beneficial ownership in the Common Stock or dispose of any or all of its beneficial ownership in the Shares depending upon an ongoing evaluation of the investment in the interests, prevailing market conditions, investment and disposition opportunities, liquidity requirements of the Reporting Person and/or other investment considerations. No Reporting Person has made a determination regarding a maximum or minimum amount of investment in the beneficial ownership interests in the Common Stock, which it may hold at any point in time.
    Except to the extent the foregoing may be deemed a plan or proposal, none of the Reporting Persons has any plans or proposals which relate to, or could result in, any of the matters referred to in paragraphs (a) through (j), inclusive, of the instructions to Item 4 of Schedule 13D. The Reporting Persons may, at any time and from time to time, review or reconsider their position and/or change their purpose and/or formulate plans or proposals with respect thereto.

    Item 5.  Interest in Securities of the Issuer.


    a.
    Based on the Issuer’s Quarterly Report filed on Form 10-Q that was filed with the U.S. Securities and Exchange Commission (the “SEC”) on August 13, 2024, the percentages used herein are based on 2,495,694 shares of Common Stock outstanding as of July 31, 2024.


    b. Each of the Investment Manager and the General Partner may be deemed to have the shared power to vote or direct the vote of (and the shared power to dispose or direct the disposition of) 140,974 Shares through the Fund’s beneficial ownership of the Shares.  By virtue of his position as the managing member of the General Partner, principal of the Investment Manager and direct of the Fund, Chun R. Ding may be deemed to have the shared power to vote or direct the vote of (and the shared power to dispose or direct the disposition of) the Shares and, therefore, Chun R. Ding may be deemed to be the beneficial owner of the Share for purposes of this Statement.


    c. The following describes all transactions in the Issuer’s Common Stock that were effected during the past 60 days by the Reporting Persons:

    Transaction Date
    Nature of Transaction
    Shares
    Price per Share
    9/19/24
    Purchase
    50,000 $17.861
           
    9/20/24
    Purchase
    15,340
    $16.232
           
    9/23/24
    Purchase
    3,022
    $16.25
           
    9/24/24
    Purchase
    2,098
    $16.25
           
    9/25/24
    Purchase
    19,512
    $15.923
           
    9/26/24
    Purchase
    10,028
    $15.644
           
    9/27/24
     Purchase 1,100
    $15.245
           
    10/30/24
    Purchase
    28,900
    $13.05
           
    10/31/24
    Purchase
    557
    $12.55
           
    11/04/24
    Purchase
    10,417
    $21.206


    1
    The prices reported are weighted average prices. These Shares were purchased in multiple transactions at prices ranging from $16.22 to $18.55. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the SEC staff, upon request, all information regarding the number of Shares purchased at each price within the ranges set forth in Footnotes 1 through 6 herein.

    2
    These Shares were purchased in multiple transactions at prices ranging from $15.99 to $16.25.

    3
    These Shares were purchased in multiple transactions at prices ranging from $15.24 to $16.25.

    4
    These Shares were purchased in multiple transactions at prices ranging from $15.01 to $15.76.

    5
    These Shares were purchased in multiple transactions at prices ranging from $15.17 to $15.25.

    6
    These Shares were purchased in multiple transactions at prices ranging from $20.76 to $21.25.




    7




    d.
    No person other than a Reporting Person has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, Common Stock beneficially owned by the Reporting Persons.


    e.
    Not applicable.


    Item 6.  Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.

    The Reporting Persons do not have any contracts, arrangements, understandings or relationships (legal or otherwise) with respect to the Common Stock reported herein.


    Item 7.  Material to Be Filed as Exhibits.
     
    There is filed herewith as Exhibit 1 a written agreement relating to the filing of joint acquisition statements as required by Section 240.13d-1(k) under the Securities Exchange Act of 1934, as amended.
     
     

    8


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated:  November 5, 2024


     
    /s/ Kelvin Koo
     
     
    CRCM LLC,
    On its own behalf and as the General Partner of
    CRCM LP, and as the Investment Manager of
    CRCM Institutional Master Fund (BVI), Ltd.

         
      By:  Kelvin Koo, Attorney-in-Fact for Chun R. Ding, Member  
         
      /s/ Kelvin Koo  
     
    By:  Kelvin Koo, Attorney-in-Fact for Chun R. Dung
     

     
     


    9



    Exhibit Index


    Exhibit 1 Joint Acquisition Statement Pursuant to Section 240.13d-1(k)
     
     
    Exhibit 2
    Power of Attorney appointing Kelvin Koo as true and lawful attorney-in-fact for Chun Ding (previously filed)
     
     





     









    10


    EXHIBIT 1




    JOINT ACQUISITION STATEMENT
    PURSUANT TO SECTION 240.13d-1(k)
     
         
    The undersigned acknowledge and agree that the foregoing statement on Schedule 13D is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13D shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements.  The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him, her or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the other entities or persons, except to the extent that he, she or it knows or has reason to believe that such information is inaccurate.

    Dated: November 5, 2024



     
     
    /s/ Kelvin Koo
     
     
    CRCM LLC,
    On its own behalf and as the General Partner of
    CRCM LP, and as the Investment Manager of
    CRCM Institutional Master Fund (BV), Ltd.

         
      By:  Kelvin Koo, Attorney-in-Fact for Chun R. Ding, Member  
         
      /s/ Kelvin Koo  
     
    By:  Kelvin Koo, Attorney-in-Fact for Chun R. Dung
     
     
     











    11
    Get the next $OMIC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $OMIC

    DatePrice TargetRatingAnalyst
    8/17/2022$10.00 → $4.50Buy → Neutral
    UBS
    8/10/2022$3.50Buy → Neutral
    Goldman
    8/10/2022$3.00Buy → Underperform
    BofA Securities
    1/7/2022$21.00Neutral → Buy
    BofA Securities
    10/15/2021Outperform
    Cowen
    More analyst ratings

    $OMIC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Singular Highlights Key G4X™ Launch Milestones and Showcases Groundbreaking 3D Spatial Multiomic Performance at AGBT

      SAN DIEGO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc., an innovator in high-throughput spatial multiomics technologies designed to advance precision medicine, today announced key development milestones for its G4X™ Spatial Sequencer at the Advances in Genome Biology and Technology (AGBT) conference in Marco Island, Florida. G4X Early Access Program Ongoing and Broader Availability on Track The G4X Early Access Program is currently underway at Beth Israel Deaconess Medical Center and Vanderbilt University Medical Center, providing valuable feedback highlighting the platform's real-world potential. "As the first early access site, we've had the chance to

      2/24/25 8:00:00 AM ET
      $OMIC
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Singular Genomics Announces Closing of Acquisition by Deerfield Management

      SAN DIEGO, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (NASDAQ:OMIC), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower researchers and clinicians, announced today the closing of its acquisition by an affiliate of Deerfield Management Company, L.P.    On December 23, 2024, Singular Genomics announced that Deerfield had signed a definitive agreement to acquire all of the outstanding shares of Singular Genomics common stock not currently owned by Deerfield for $20.00 per share in cash. Following the satisfaction of customary conditions, including a vote of the holders of Singular Genomics' common stock to approv

      2/21/25 9:56:26 AM ET
      $OMIC
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Singular Genomics Enters into Agreement to be Acquired by Deerfield for $20.00 in Cash per Share

      SAN DIEGO, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (NASDAQ:OMIC) ("Singular Genomics" or the "Company"), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower researchers and clinicians, today announced that it has entered into a definitive merger agreement whereby an affiliate of Deerfield Management Company, L.P. will acquire Singular Genomics in an all-cash transaction for $20.00 per share. The $20.00 per share represents 254% premium to the last closing share price for Singular's common stock prior to the September 12, 2024 public disclosure of Deerfield's initial acquisition proposal. The Singular Genomic

      12/23/24 8:30:00 AM ET
      $OMIC
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $OMIC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Singular Genomics Systems downgraded by UBS with a new price target

      UBS downgraded Singular Genomics Systems from Buy to Neutral and set a new price target of $4.50 from $10.00 previously

      8/17/22 9:15:00 AM ET
      $OMIC
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Singular Genomics Systems downgraded by Goldman with a new price target

      Goldman downgraded Singular Genomics Systems from Buy to Neutral and set a new price target of $3.50

      8/10/22 6:31:06 AM ET
      $OMIC
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Singular Genomics Systems downgraded by BofA Securities with a new price target

      BofA Securities downgraded Singular Genomics Systems from Buy to Underperform and set a new price target of $3.00

      8/10/22 6:30:40 AM ET
      $OMIC
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $OMIC
    SEC Filings

    See more
    • Singular Genomics Systems Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Material Modification to Rights of Security Holders, Changes in Control of Registrant

      8-K - Singular Genomics Systems, Inc. (0001850906) (Filer)

      2/27/25 1:42:39 PM ET
      $OMIC
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Amendment: SEC Form SCHEDULE 13D/A filed by Singular Genomics Systems Inc.

      SCHEDULE 13D/A - Singular Genomics Systems, Inc. (0001850906) (Subject)

      2/25/25 9:18:06 PM ET
      $OMIC
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form EFFECT filed by Singular Genomics Systems Inc.

      EFFECT - Singular Genomics Systems, Inc. (0001850906) (Filer)

      2/24/25 12:15:05 AM ET
      $OMIC
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $OMIC
    Leadership Updates

    Live Leadership Updates

    See more
    • Singular Genomics Appoints Genomics Veteran Marcia Eisenberg, Ph.D., to Board of Directors

      SAN DIEGO, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (NASDAQ:OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced the appointment of Marcia Eisenberg, Ph.D., to the Company's Board of Directors. Dr. Eisenberg currently serves as Senior Vice President and Enterprise Chief Scientific Officer at Labcorp (NYSE:LH) and brings more than 30 years of experience with molecular genetics, DNA testing, biotechnology, and molecular oncology. "Marcia's deep and diverse genomics expertise will be an asset to Singular as we drive our business strategy forward, and we are delighted to w

      8/8/23 4:05:00 PM ET
      $LH
      $OMIC
      Medical Specialities
      Health Care
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Singular Genomics Appoints Sam Ropp, Ph.D., as Chief Commercial Officer

      SAN DIEGO, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (NASDAQ:OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced the appointment of Sam Ropp, Ph.D., as Chief Commercial Officer. In this role, Dr. Ropp will oversee the company's commercial function, including commercialization of the G4 Sequencing Platform. He will report to Drew Spaventa, Chief Executive Officer and Founder of Singular Genomics. The company also announced the appointment of Jeff Bullard as Head of Sales for North America. "As an accomplished life science leader, Sam brings the deep knowledge and experi

      8/2/22 7:30:00 AM ET
      $OMIC
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Singular Genomics Appoints Genomics Research Pioneer Elaine R. Mardis, Ph.D., to Board of Directors

      LA JOLLA, Calif., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (NASDAQ:OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced the addition of Elaine R. Mardis, Ph.D., to the Company's Board of Directors. Dr. Mardis is a pioneering researcher internationally recognized in cancer genomics with a focus on the application of genomic technologies to improve the understanding of human disease and the precision of medical diagnosis, prognosis and treatment. "We are thrilled to have Elaine join the Board of Directors. She brings the rare combination of world-class scientific, indust

      1/6/22 4:05:00 PM ET
      $OMIC
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $OMIC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Singular Genomics Systems Inc.

      SC 13D/A - Singular Genomics Systems, Inc. (0001850906) (Subject)

      11/22/24 7:55:51 PM ET
      $OMIC
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13D filed by Singular Genomics Systems Inc.

      SC 13D - Singular Genomics Systems, Inc. (0001850906) (Subject)

      11/5/24 7:29:21 PM ET
      $OMIC
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Amendment: SEC Form SC 13D/A filed by Singular Genomics Systems Inc.

      SC 13D/A - Singular Genomics Systems, Inc. (0001850906) (Subject)

      11/1/24 7:54:29 PM ET
      $OMIC
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $OMIC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $OMIC
    Financials

    Live finance-specific insights

    See more
    • Large owner Tang Kevin bought $1,806,220 worth of shares (122,416 units at $14.75) (SEC Form 4)

      4 - Singular Genomics Systems, Inc. (0001850906) (Issuer)

      9/18/24 4:31:08 PM ET
      $OMIC
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Spaventa Andrew bought $49,612 worth of shares (118,468 units at $0.42) (SEC Form 4)

      4 - Singular Genomics Systems, Inc. (0001850906) (Issuer)

      11/20/23 4:31:38 PM ET
      $OMIC
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Glezer Eli N. bought $85,640 worth of shares (200,000 units at $0.43), increasing direct ownership by 5% to 4,570,000 units (SEC Form 4)

      4 - Singular Genomics Systems, Inc. (0001850906) (Issuer)

      11/20/23 4:30:55 PM ET
      $OMIC
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Singular Genomics Reports Recent Updates and Third Quarter 2024 Financial Results

      SAN DIEGO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (NASDAQ:OMIC), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower researchers and clinicians, today highlighted recent corporate achievements and reported financial results for the third quarter ended September 30, 2024. "In the third quarter, we made significant progress in the development of the G4X spatial sequencer," said Drew Spaventa, Chairman and Chief Executive Officer of Singular Genomics. "We are encouraged by the interest in the G4X and validation received through the expansion of our Spatial Technology Access Services project funnel, which reinfo

      11/12/24 4:05:00 PM ET
      $OMIC
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Singular Genomics Reports Recent Highlights and Second Quarter 2024 Financial Results

      SAN DIEGO, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (NASDAQ:OMIC), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower researchers and clinicians, today highlighted recent corporate achievements and reported financial results for the second quarter ended June 30, 2024. "It was another busy and productive quarter for our team as we progressed development of the G4X Spatial Sequencer while supporting our G4 customers," said Drew Spaventa, Chairman and Chief Executive Officer of Singular Genomics. "The early interest in our Spatial Technology Access Services is an encouraging sign that the unique capabilities and

      8/13/24 4:05:00 PM ET
      $OMIC
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Singular Genomics to Report Second Quarter 2024 Financial Results on August 13, 2024

      SAN DIEGO, July 30, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (NASDAQ:OMIC), a company leveraging novel next-generation sequencing (NGS) and spatial multiomics technologies to empower researchers and clinicians, today announced that it will report financial results for the second quarter ended June 30, 2024 after the market close on Tuesday, August 13, 2024. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by dialing 1-888-506-0062 for domestic callers or 1-973-528-0011 for international callers and using conference ID 66

      7/30/24 5:05:42 PM ET
      $OMIC
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $OMIC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Tang Kevin returned 372,000 shares to the company (SEC Form 4)

      4 - Singular Genomics Systems, Inc. (0001850906) (Issuer)

      2/27/25 8:54:47 PM ET
      $OMIC
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Chief Executive Officer Spaventa Andrew returned 143,310 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - Singular Genomics Systems, Inc. (0001850906) (Issuer)

      2/25/25 8:12:58 PM ET
      $OMIC
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Chief Financial Officer Meeter Dalen returned 9,502 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - Singular Genomics Systems, Inc. (0001850906) (Issuer)

      2/25/25 8:11:40 PM ET
      $OMIC
      Biotechnology: Laboratory Analytical Instruments
      Industrials